Collaborative Review – Prostate Cancer Testosterone and Prostate Cancer: Revisiting Old Paradigms

1181. [28] Agarwal PK, Oefelein MG. Testosterone replacement therapy after primary treatment for prostate cancer. J Urol 2005;173: 533–6.[29] Kaufman JM, Graydon RJ. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol 2004;172:920–2.[30] Morgentaler A. Testosterone therapy in men with prostate cancer: scientific and ethical considerations. J Urol 2009;181:972–9. [31] Carson III C, Rittmaster R. The role of dihydrotestosterone in benign prostatic hyperplasia. Urology 2003;61:2–7.[32] Fowler Jr JE, Whitmore Jr WF. The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J Urol 1981;126:372–5.[33] Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of andro-gen-dependent growth. Eur Urol 2009;55:310–21.[34] Traish AM, Williams DF, Hoffman ND, Wotiz HH. Validation ofthe exchange assay for the measurement of androgen receptors in human and dog prostates. Prog Clin Biol Res 1988;262:145–60.[35] Ho SM, Damassa D, Kwan PW, Seto HS, Leav I. Androgen receptor levels and androgen contents in the prostate lobes of intact andtestosterone-treated Noble rats. J Androl 1985;6:279–90.[36] Marks LS, Mostaghel EA, Nelson PS. Prostate tissue androgens:history and current clinical relevance. Urology 2008;72:247–54. [37] Prout Jr GR, Brewer WR. Response of men with advanced prostaticcarcinoma to exogenous administration of testosterone. Cancer1967;20:1871–8.[38] Marks LS, Mazer NA, Mostaghel E, et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onsethypogonadism: a randomized controlled trial. JAMA 2006;296:2351–61. [39] El-Sakka AI, Hassoba HM, Elbakry AM, Hassan HA. Prostatic specificantigen in patients with hypogonadism: effect of testosteronereplacement. J Sex Med 2005;2:235–40.[40] Bhasin S, Woodhouse L, Casaburi R, et al. Testosterone dose– response relationships in healthy young men. Am J Physiol Endo-crinol Metab 2001;281:E1172–81.[41] Cooper CS, Perry PJ, Sparks AE, MacIndoe JH, Yates WR, Williams RD. Effect of exogenous testosterone on prostate volume, serumand semen prostate specific antigen levels in healthy young men.J Urol 1998;159:441–3.[42] Behre HM, Bohmeyer J, Nieschlag E. Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clin Endocrinol 1994;40:341–9.[43] Morgentaler A. Two years of testosterone therapy associated withdecline in prostate-specific antigen in a man with untreated prostate cancer. J Sex Med 2009;6:574–7.[44] Morgentaler A, Bruning III CO, DeWolf WC. Occult prostate cancerin men with low serum testosterone levels. JAMA 1996;276: 1904–6.[45] Morgentaler A, Rhoden EL. Prevalence of prostate cancer amonghypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less. Urology 2006;68:1263–7. [46] Rhoden EL, Riedner CE, Morgentaler A. The ratio of serum testos-terone-to-prostate specific antigen predicts prostate cancer in hypogonadal men. J Urol 2008;179:1741–4, discussion 1744–5. [47] Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level 4.0 ng/mL. N Engl J Med 2004;350:2239–46. [48] Imamoto T, Suzuki H, Fukasawa S, et al. Pretreatment serum testosterone level as a predictive factor of pathological stage inlocalized prostate cancer patients treated with radical prostatectomy. Eur Urol 2005;47:308–12. [49] Schatzl G, Madersbacher S, Thurridl T, et al. High-grade prostate cancer is associated with low serum testosterone levels. Prostate2001;47:52–8.[50] Yano M, Imamoto T, Suzuki H, et al. The clinical potential of pretreatment serum testosterone level to improve the efficiency of prostate cancer screening. Eur Urol 2007;51:375–80. [51] Massengill JC, Sun L, Moul JW, et al. Pretreatment total testosteronelevel predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol 2003;169:1670–5. [52] Isom-Batz G, Bianco Jr FJ, KattanMW,Mulhall JP, Lilja H, Eastham JA.Testosterone as a predictor of pathological stage in clinically localized prostate cancer. J Urol 2005;173:1935–7. E U RO P E AN URO LOG Y 5 6 ( 2 0 0 9 ) 4 8 – 5 656 [53] Yamamoto S, Yonese J, Kawakami S, et al. Preoperative serum testosterone level as an independent predictor of treatment failurefollowing radical prostatectomy. Eur Urol 2007;52:696–701.[54] Morgentaler A. Testosterone deficiency and prostate cancer: emer-ging recognition of an important and troubling relationship. Eur Urol 2007;52:623–5.[55] Nishiyama T, Ikarashi T, Hashimoto Y, Suzuki K, Takahashi K.Association between the dihydrotestosterone level in the prostate and prostate cancer aggressiveness using the Gleason score. J Urol2006;176:1387–91.[56] Grasso M, Buonaguidi A, Mondina R, et al. Plasma sex hormonebinding globulin in patients with prostatic carcinoma. Cancer 1990;66:354–7.[57] Salonia A, Briganti A, Gallina A, et al. Sex hormone-binding globu-lin: a novel marker for nodal metastases prediction in prostatecancer patients undergoing extended pelvic lymph node dissection. Urology 2009;73:850–5.[58] Loughlin KR, Richie JP. Prostate cancer after exogenous testosteronetreatment for impotence. J Urol 1997;157:1845. [59] Gaylis FD, Lin DW, Ignatoff JM, Amling CL, Tutrone RF, Cosgrove DJ.Prostate cancer in men using testosterone supplementation. J Urol2005;174:534–8, discussion 538.[60] Jackson JA, Waxman J, Spiekerman AM. Prostatic complications of testosterone replacement therapy. Arch Intern Med 1989;149:2365–6.[61] Bhasin S, Buckwalter JG. Testosterone supplementation in older men: a rational idea whose time has not yet come. J Androl2001;22:718–31.[62] Rhoden EL, Morgentaler A. Risks of testosterone-replacement ther-apy and recommendations for monitoring. N Engl J Med 2004;350: 482–92.[63] Calof OM, Singh AB, Lee ML, et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A BiolSci Med Sci 2005;60:1451–7.[64] Rhoden EL, Morgentaler A. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 yearof treatment in men with prostatic intraepithelial neoplasia. J Urol2003;170:2348–51. [65] Umekita Y, Hiipakka RA, Kokontis JM, Liao S. Human prostatetumor growth in athymic mice: inhibition by androgens andstimulation by finasteride. Proc Natl Acad Sci U S A 1996;93:11802–7. [66] Chuu CP, Hiipakka RA, Fukuchi J, Kokontis JM, Liao S. Androgencauses growth suppression and reversion of androgen-independentprostate cancer xenografts to an androgen-stimulated phenotypein athymic mice. Cancer Res 2005;65:2082–4. [67] Chuu CP, Hiipakka RA, Kokontis JM, Fukuchi J, Chen RY, Liao S.Inhibition of tumor growth and progression of LNCaP prostatecancer cells in athymic mice by androgen and liver X receptor agonist. Cancer Res 2006;66:6482–6.[68] Hsing AW, Chu LW, Stanczyk FZ. Androgen and prostate cancer: isthe hypothesis dead? Cancer Epidemiol Biomarkers Prev2008;17:2525–30. [69] Morales A, Black AM, Emerson LE. Testosterone administration tomen with testosterone deficiency syndrome after external beamradiotherapy for localized prostate cancer: preliminary observations. BJU Int 2009;103:62–4.[70] CarpenterWR, RobinsonWR, Godley PA. Getting over testosterone:postulating a fresh start for etiologic studies of prostate cancer.J Natl Cancer Inst 2008;100:158–9.